Gilead Sciences | GILD - Debt


Gilead Sciences reported $22.17B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026